Markers of high-risk cutaneous melanoma: Is there a winning combination for individualized prognosis?

Journal of Cutaneous Pathology

Volumn 32, Issue 10, 2005, Pages 700-703

  Carlson, J Andrew ^a   Ross, Jeffrey ^a   Murphy, Michael ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CD44V ANTIGEN; CYCLIN A; CYCLIN D3; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GELATINASE A; HLA ANTIGEN; HMB 45 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; KI 67 ANTIGEN; METALLOTHIONEIN; MYC PROTEIN; OSTEONECTIN; PROTEIN BCL 6; PROTEIN P53; TRANSCRIPTION FACTOR AP 2; TUMOR MARKER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANTIGEN EXPRESSION; CELL CYCLE; EXCISION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; INDIVIDUALIZATION; LETTER; MELANOMA; METASTASIS; MISMATCH REPAIR; PROGNOSIS; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION;

CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; MELANOMA; PROGNOSIS; RISK ASSESSMENT; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 28344431969     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0303-6987.2005.00389.x     Document Type: Letter

References (23)

1. Li Q, Murphy M, Ross J, Sheehan C, Carlson JA. Skp2 and p27 expression in melanocytic nevi and melanoma: an inverse relationship. J Cutan Pathol 2004; 31: 633.
2. Simonart T, Heenen M. How far can we trust cell-cycle biomarkes for the identification of high-risk melanoma patients? J Cutan Pathol 2005; 32: 383-4.
3. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97: 1488.
4. Roesch A, Vogt T, Stolz W, Dugas M, Landthaler M, Becker B. Discrimination between gene expression patterns in the invasive margin and the tumour core of malignant melanomas. Melanoma Res 2003; 13: 503.
5. Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 2002; 20: 2530.
6. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635.
7. Cochran AJ, Elashoff D, Morton DL, Elashoff R. Individualized prognosis for melanoma patients. Hum Pathol 2000; 31: 327.
8. Clark WH, Elder DE, Guerry D, IV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81: 1893.
9. Szymik B, Woosley JT. Further validation of the prognostic model for stage I malignant melanoma based on tumor progression. J Cutan Pathol 1993; 20: 50.
10. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 2004; 22: 3668.
11. Carlson J, Ross J, Slominski A, Mysliborski J, Hill J, Mihm CM Jr. Molecular diagnostics in melanoma. J Am Acad Dermatol 2005; 52: 743-75.
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57.
13. Reed JA, Albino AP. Update on diagnostic and prognostic markers in cutaneous malignant melanoma. Dermatol Clin 1999; 17: 631.
14. Alonso SR, Ortiz P, Pollan M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004; 164: 193.
15. Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O, Maelandsmo GM. Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol 2004; 17: 990.
16. Florenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol 1998; 153: 305.
17. Daniotti M, Oggionni M, Ranzani T, et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 2004; 23: 5968.
18. Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol 2004; 11: 426.
19. Sauroja I, Smeds J, Vlaykova T, et al. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer 2000; 28: 404.
20. Murphy M, Carlson JA. Can we reliably use markers of cell cycle regulation (e.g. Ki-67, p21, p27, p53) to differentiate between benign and malignant skin tumors? J Cutan Pathol 2001; 28: 219.
21. Murphy M, Carlson JA, Keough MP, Claffey KP, Signoretti S, Loda M. Hypoxia regulation of the cell cycle in malignant melanoma, putative role for the cyclin-dependent kinase inhibitor p27. J Cutan Pathol 2004; 31: 477.
22. Svensson S, Nilsson K, Ringberg A, Landberg G. Invade or proliferate? Two contrasting events in malignant behavior governed by p16 (INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res 2003; 63: 1737.
23. Nilsson K, Svensson S, Landberg G. Retinoblastoma protein function and p16INK4a expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16INK4a expression and infiltrative behavior. Mod Pathol 2004; 17: 1464.